WebJun 21, 2024 · The diagnosis and treatment of choroidal neovascularization (CNV) in eyes with chronic central serous chorioretinopathy (CSCR) can be challenging. The purpose of this study was to classify eyes with suspected CNV using multimodal imaging. The effect of intravitreal anti-vascular endothelial growth f … WebJun 15, 2024 · Central serous chorioretinopathy (CSCR) is a common retinal disorder that results in vision loss and alteration of visual function. 1 It is considered a pachychoroid disease, a category of diseases that …
Efficacy of Navigated Laser Photocoagulation for Chronic Central …
WebThere is sufficient scientific evidence to suggest that PDT may be a useful treatment option for chronic CSCR in the short-term. The review identifies a need for robust RCTs with longer follow-up to ascertain the role of PDT as a useful treatment option for CSCR. Photodynamic therapy for central serous chorioretinopathy Eye (Lond). WebDec 26, 2024 · CSCR often resolves spontaneously, however may persist. Chronic CSCR is defined as persistent serous detachment of duration 4 to 6 months. fm99 wnor listen live
Ganglion Cell Loss in the Course of Central Serous ... - PubMed
WebCentral serous chorioretinopathy (CSCR) is a common condition typically affecting young and middle-aged individuals. In its chronic form, it can lead to changes in retinal morphology and significant visual impairment. This disorder occurs basically in two forms: acute and chronic, depending on its duration. WebCSCR, CNV and PCV can be put together in a spectrum of ‘pachychoroid’ condition.26 AMD is the most important differential diagnosis in CSCR patients aged 50 years or more. Secondary CNV, mostly type 2, can develop in patients with chronic CSCR during follow-up or after laser photocoagulation. Polypoidal choroidal vasculopathy WebJan 25, 2024 · CSCR is a common visually disabling condition that develops in individuals up to 60 years of age, and there is no definitive treatment. Previous research suggests the mineralocorticoid receptor antagonist, eplerenone, is effective for treating CSCR; however, this drug is not licensed for the treatment of patients with CSCR. fm9 barrel swap